

ORIGINAL ARTICLE

Basic and Translational Allergy Immunology



WILEY

Impact of high-altitude therapy on type-2 immune responses in asthma patients

Tadech Boonpiyathad^{1,2,3} | Gertruda Capova^{3,4} | Hans-Werner Duchna^{3,4} | Andrew L. Croxford⁵ | Herve Farine⁵ | Anita Dreher^{1,4} | Martine Clozel⁵ | Juliane Schreiber⁴ | Petr Kubena⁴ | Nonhlanhla Lunjani^{1,3} | David Mirer¹ | Beate Rückert¹ | Pattraporn Satitsuksanoa^{1,3} | Ge Tan¹ | Peter M. A. Groenen⁵ | Eugen Bersuch^{3,4} | Mübeccel Akdis¹ | Daniel S. Strasser⁵ | Ellen D. Renner^{3,4,6} | Cezmi A. Akdis^{1,3}

¹Swiss Institute of Allergy and Asthma Research, University of Zurich, Davos, Switzerland

²Department of Medicine, Phramongkutklao Hospital, Bangkok, Thailand

³Christine Kühne Center for Allergy Research and Education, Davos, Switzerland

⁴Hochgebirgsklinik Davos, Davos, Switzerland

⁵Drug Discovery, Idorsia Pharmaceuticals Ltd., Allschwil, Switzerland

⁶Chair and Institute of Environmental Medicine – UNIKA-T, TU Munich and Helmholtz Zentrum Munich, Munich, Germany

Correspondence

Cezmi A. Akdis, Swiss Institute of Allergy and Asthma Research, Obere Strasse 22, CH-7270, Davos Platz, Switzerland.
Email: akdisac@siaf.uzh.ch

Funding information

Christine Kühne-Center for Allergy Research and Education (CK-CARE); Idorsia Pharmaceuticals

Abstract

Background: Asthma patients present with distinct immunological profiles, with a predominance of type 2 endotype. The aim of this study was to investigate the impact of high-altitude treatment on the clinical and immunological response in asthma.

Methods: Twenty-six hospitalized asthma patients (nine eosinophilic allergic; EA, nine noneosinophilic allergic; NEA and eight noneosinophilic nonallergic; NN) and nine healthy controls in high altitude for 21 days were enrolled in the study. We assessed eosinophils, T cells, Tregs, and innate lymphoid cells (ILC) from peripheral blood using flow cytometry.


Results: The number of eosinophils (both resting and activated) and chemoattractant receptor homolog expressed on Th2 cells (CRTH2)-expressing CD4⁺ and CD8⁺ T cells decreased significantly in EA patients after altitude treatment. The frequency of CRTH2⁺ Tregs as decreased significantly in all the asthma phenotypes as well as the frequency of ILC2 was significantly reduced in EA after altitude treatment. After 21 days of altitude therapy, CRTH2-expressing ILC2, CD4⁺ and CD8⁺ T cells and Treg cells showed attenuated responses to exogenous PGD2. Furthermore, PGD2 signaling via CRTH2 was found to diminish the suppressive function of CRTH2⁺ Tregs which partially normalized during high-altitude treatment. Improved asthma control was particularly evident in allergic asthma patients and correlated with decreased frequencies of CRTH2⁺ Treg cells in EA patients. Serum IL-5 and IL-13 decreased during climate treatment in asthma patients with high baseline levels.

Conclusions: Asthma treatment in high altitude reduced the type 2 immune response, corrected the increased CRTH2 expression and its dysregulated functions.

Abbreviations: CRTH2, Chemoattractant receptor homolog expressed on Th2 cells; EA, Eosinophilic allergic asthma; ILC, Innate lymphoid cells; NEA, Noneosinophilic allergic asthma; NN, Noneosinophilic nonallergic asthma; PGD2, Prostaglandin D2; Tc, T cytotoxic; Th2, T helper 2; Tregs, Regulatory T cells.

KEYWORDS

asthma phenotype, chemoattractant receptor homolog expressed on Th2 cells, eosinophils, high altitude, T cells



GRAPHICAL ABSTRACT

High-altitude therapy of asthma reduces the frequencies of chemoattractant receptor homolog expressed on Th2 cells (CRTH2) innate lymphoid cells, activated eosinophils, helper and cytotoxic T cells. CRTH2⁺ T regulatory cells are defective in their suppressive function and show less suppressive function in PGD2-stimulated cultures. High-altitude therapy improves asthma symptoms associated with the correction of dysregulated type-2 and T regulatory responses.

Abbreviations: CRTH2, Chemoattractant receptor-homologous molecule expressed on TH2 cells; PGD2, Prostaglandin D2

1 | INTRODUCTION

Subtypes of asthma defined by the type of inflammation and complex immune-regulatory networks open the opportunity for new pathway precision diagnosis and targeted treatments.^{1,2} Asthma management can be individualized not only depending on the severity of the disease, but more importantly on the phenotypic and endotypic characteristics of the patient. An asthma endotype is defined by a distinct pathophysiological mechanism, such as the type 2 endotype.^{3,4} Allergic asthma is the most common asthma phenotype with an earlier onset.⁵⁻⁷ Nonallergic or intrinsic asthma includes a subset of patients with asthma without allergic sensitization.^{8,9} These patients show quite variable response to standard therapy.⁵ Eosinophilic asthma is defined as blood eosinophilia (>350 cells/ μ L), associated with tissue and sputum eosinophilia, thickening of the basement membrane zone and often by good response to inhaled corticosteroid therapy.^{10,11} Improvements in the blood and tissue eosinophilia are associated with fewer exacerbations and lower healthcare costs.⁶ Particularly, CD69 expression on eosinophils is an indicator for eosinophil activation.¹² It is expressed at a low level on unstimulated blood eosinophils and upregulated by interleukin (IL)-5.⁷

Chemoattractant receptor homolog expressed on Th2 cells (CRTH2) represents one of two functional prostaglandin D2 (PGD2)

receptors. CRTH2 is expressed on various types of cells; eosinophils, Th2 cells, ILC2, basophils, CD8⁺ T cells, mast cells, macrophages, monocytes, and dendritic cells.^{13,14} The PGD2/CRTH2 axis has emerged into a potential pathophysiological factor for allergy and asthma.¹⁵ In allergic asthma patients, the production of PGD2 is increased by allergen exposure.¹⁶ After an allergen challenge, the concentration of PGD2 is increased in bronchoalveolar lavage fluid, and its 9 α , 11 β -PGF2 metabolite is increased in plasma.¹⁷ PGD2 effects are mediated partially by prostaglandin D2 receptor 1 (DP1) which causes bronchoconstriction, vasodilation, and increase in capillary permeability and mucus production.¹⁸ CRTH2 on immune cells is involved in the migration and activation of Th2 cells, eosinophils, basophils, and ILC2, and with production of type 2 cytokines IL-4, IL-5, and IL-13.¹⁹ Elevated levels of peripheral CD4⁺CRTH2⁺ T cells is a feature of severe allergic asthma.²⁰

Innate lymphoid cells 2s and Th2 cells are a significant source of type 2 cytokines and play a role in eosinophilic inflammatory response, allergy and remodeling in asthma.^{21,22} Increased circulating and sputum IL-5 and IL-13-producing ILC2s were detected in severe asthma compared to mild asthma patients.¹⁵ Furthermore, increased numbers of IL-5⁺ and IL-13⁺ ILC2s were found in sputum after allergen challenge in asthma patients.²³ Moreover, increased frequency of IL-13-producing ILC2 was enhanced by PGD2

that was co-stimulated with IL-2, IL-25, and IL-33 in asthma patients.^{24,25} IL-13-expressing ILC2 and Th2 cells are also responsible for bronchial epithelial tight junction barrier leakiness in asthma patients.^{26,27}

Several studies have demonstrated the efficacy of altitude therapy in treating asthma patients. The hypothesis the effect of high-altitude treatment combines anti-inflammatory treatment as allergen avoidance, low pressure, less stress, less particle exposure and exposure to sunshine stimulate vitamin D photosynthesis. High-altitude treatment showed significantly decreased monocyte activation and CRTH2 expression on CD4⁺CD25⁺ T cell in asthmatic patients.²⁸ In children with atopic dermatitis, high-altitude treatment showed significant reductions in memory Tregs, transitional B cells, and plasmablasts. Concomitant, increases in memory B cells, effector memory CD8⁺ T cells, central memory CD4⁺ T cells, and CCR7⁺ Th2 cells were reported.²⁹ However, detailed changes to the immunological landscape after altitude therapy has not been described in asthma patient subgroups. The present study assesses the kinetics of immunological changes in different asthma phenotypes in response to treatment in high altitude with specific focus on the CRTH2 receptor and its functions on ILCs, CD4 and CD8 T cell subsets, Tregs, and eosinophils during the treatment.

2 | METHODS

2.1 | Subjects

This observational study enrolled 29 adult inpatients (14 males, 15 females and average aged 53.3 years) with asthma at the Pulmonary Clinic (1560 m above sea level). Patients had an average stay of 21 days in Davos. All patients came from low-altitude locations and chose their 21 days stay in Davos in to receive high-altitude treatment. Nine healthy control subjects (5 males and 4 females) who visited Davos for the first time were recruited in the study (Table S1). All patients were treated with short-acting inhaled beta-agonists for quick relief asthma symptoms and long-acting inhaled beta-agonists plus inhaled corticosteroid (Table S2). No systemic corticosteroid treatment was used in the study. All patients showed good compliance with their treatment and proper inhalation technique of inhaled medication.

Medical history, physical examination, pulmonary function test, and exhaled nitric oxide (FeNO₂) measurement were performed during the first days of admission to the hospital. The patients received questionnaires on asthma control test (ACT) score.³⁰ Lithium heparin-coagulated blood was collected from patients with asthma and healthy control subjects at baseline and 21 days. Total eosinophil counts > 350 cells/ μ L classified as eosinophilia. Medical history of skin pricking test or allergen-specific IgE was assessed for allergy diagnosis. All subjects gave informed consent before participation in the study. The study was approved by the Kanton Zurich Ethical Committee.

2.2 | Flow cytometry staining

Whole blood was collected into lithium heparin tubes and stored at room temperature until analyses. First, 500 μ L of whole blood were stained with 0.5 μ L viability dye eFluor 780 (eBioscience) for 30 minutes 4°C, protect from light. After that, whole blood was lysed with 500 μ L of red blood cell soft lysis buffer for 10 minutes at room temperature and then washed twice with phosphate buffer saline (PBS). Cells were then stained with anti-CRTH2-Alexa Flour 647 (AF 647) (BD Biosciences) for 15 minutes at room temperature and washed with PBS. Cells were stained extracellularly for markers associated with eosinophils, T cells, and innate lymphoid cells. Flow cytometry was performed using a Gallios (Beckman Coulter). Data and figures were analyzed with Kaluza Software (Beckman Coulter). For a detailed description of reagents and procedures, see the Method section in Appendix S1.

2.3 | Stimulation of the cells with PGD2

Fresh whole blood stimulation with PGD2 was performed to evaluate the activation of CRTH2 expressing ILCs and T cell subsets. DK-PGD2 (Caymanchem) from a stock solution (10 mmol/L) was diluted to a 200 μ mol/L solution and then 500 μ L whole blood was stimulated with 2.5 μ L of PGD2 of 200 μ mol/L to a final concentration of 1 μ mol/L for 1 hour. Then, whole blood was stained with viability dye, lysis of red blood cells and surface mAbs against cell surface molecules as previously described above.

2.4 | Suppression assay for Tregs

Peripheral blood mononuclear cells were purified CRTH2⁺CD4⁺CD25⁺CD127⁻ (CRTH2⁺ Tregs), CRTH2⁻CD4⁺CD25⁺CD127⁻ (CRTH2⁻ Tregs), and CD4⁺CD25⁻ T cells (T effector cells) by using FACSria III (Beckton Dickinson). T effector cells were stained with CellTrace violet cells proliferation kit (ThermoFisher), according to the manufacturer's instructions. Then, Treg, T effector, and irradiated T cells were cultured with anti-CD3/anti-CD28 coated bead and IL-2 in 96 U bottom well plate for 5 days. Cells were also stimulated with PGD2 on day 0 to compare the suppressive function between with and without PGD2 stimulation. The vehicle in PGD2 stimulation was 10% ethanol and diluted as the same PGD2 dilution. For a detailed description of reagents and procedures, see the Method section in Appendix S1.

2.5 | Detection of cytokines in serum and supernatant

Serum IL-13 levels were measured using the Erenna Instrument (Merck KGaA). Serum IL-5 levels were measured on the Ella system (ProteinSimple). Serum Eosinophil-derived neurotoxin (EDN) levels were analyzed using an IVD ELISA from Immundiagnostik AG.

2.6 | Statistical analysis

Statistical analysis was performed using GraphPad Prism 7.0 (GraphPad Software). Baseline subject characteristics data were analyzed using either the chi-squared test or 2-way ANOVA. Nonparametric Wilcoxon matched pair test was used to calculate differences between time points. Repeated ANOVA and Tukey's multiple comparisons were used to calculate differences between the groups. Data were presented as mean \pm standard error mean (SEM). *P* values of less than .05 were considered significant.

3 | RESULTS

3.1 | Patients' characteristics

Nine eosinophilic allergic asthma (EA), nine noneosinophilic allergic asthma (NEA), eight noneosinophilic nonallergic (NN) patients, and nine healthy controls (HC) completed the study. Three asthmatic patients dropped out of the study since they stayed shorter than 21 days in the hospital but not because of therapy responses. The baseline subject characteristics are shown in Table S1. No significant differences in the average age, gender proportion, body mass index, family history of asthma, history of past smoking, total IgE levels, the lung function test, the severity of asthma (as graded by pulmonary function), and asthma control were observed between the asthma groups. NEA patients had longer durations of asthma compared to EA and NN patients.

3.2 | High altitude decreased circulating eosinophils and activated CRTH2⁺ eosinophils after treatment

Total numbers of eosinophils were significantly decreased in the patients with EA after 21 days of therapy (Figure 1A). Activation markers of these eosinophils were then assayed by flow cytometry (Figure S1A). A significant decrease compared to baseline was observed in the number of activated CRTH2⁺ eosinophils (CD11b⁺CD16⁺Siglec8⁺CCR3⁺CRTH2⁺CD69⁺) in EA patients (Figure 1B and Figure S1B). Activated eosinophils (CD11b⁺CD16⁺Siglec8⁺CD69⁺) and activated CRTH2⁺ eosinophils (CD11b⁺CD16⁺Siglec8⁺CCR3⁺CRTH2⁺CD69⁺) were higher in EA compared with other groups at baseline and decreased after treatment (Figure S2A and B). There was no statistically significant change in activated CRTH2⁺ eosinophils. The IL-5, IL-13, and EDN levels in EA patients' sera at baseline were higher compared to other groups (Figure 1C). Serum IL-5 and IL-13 levels decreased in patients with high baseline levels (Figure 1C). After 21-day treatment, the mean serum IL-5, IL-13, and EDN levels were still higher in EA patients than other asthma subgroups. Moreover, serum IL-5 and IL-13 in EA patients correlated with the absolute total number of eosinophils in EA patients (Figure 1D). EDN levels correlated with the absolute total number of eosinophils in EA and NEA patients (Figure 1E).

3.3 | High altitude decreased CRTH2 expression on T cell subsets after treatment

To determine the changes in T cell subsets occurring after 21 days of therapy, we analyzed CD4⁺, CD8⁺, and CD4⁺CD25⁺CD127⁺ (Treg) populations (Figure S3). The absolute numbers of lymphocytes were significantly decreased in EA and NN patients after 21 days (Figure S4A). The total numbers of CD4⁺ T cells also decreased in EA after treatment but no significant changes in Treg cells were observed (Figure S4B and C). The absolute numbers of CD8⁺ T cells at baseline were higher in NN patients than EA patients (Figure S4D).

Next, we analyzed CRTH2 expression on T cell subsets. Patients with EA and NEA had significantly more absolute counts and percentage of CRTH2⁺ T-helper (Th) (CD3⁺CD4⁺CD25⁺CRTH2⁺) cells compared to healthy controls at baseline (Figure 2A and Figure S5A). After altitude therapy, EA and NEA patients showed a reduction in CRTH2⁺ Th cells (Figure 2A). The frequency and absolute numbers of CRTH2⁺ Tregs (CD3⁺CD4⁺CD25⁺CD127⁺CRTH2⁺) were higher at baseline in EA and NEA patients than healthy controls (Figure 2B). Interestingly, we observed significantly reduced CRTH2⁺ Treg cells among all asthma phenotypes after 21 days of treatment in high altitude (Figure 2B). Before treatment, the frequency and absolute numbers of CRTH2⁺ Tc (CD3⁺CD8⁺CRTH2⁺) cells revealed also increased in EA and NEA patients compared with healthy controls (Figure 2C). During the 21 days of treatment, CD8⁺CRTH2⁺ T cells showed a decrease in EA and NEA patients (Figure 2C). The results of the CRTH2 expression on T cell subsets are shown in Figure S5A-C. Furthermore, we analyzed how CRTH2 expression on T cell subsets correlates with serum IL-5 and IL-13 levels. The frequency and absolute numbers of CRTH2⁺ Th cells showed a negative correlation with serum IL-13 levels in EA patients (Figure 2D). This analysis demonstrates that 21 days of high-altitude treatment reduces frequencies and cellularity of CRTH2-expressing T cell subsets.

3.4 | High altitude reduced CRTH2 expression on ILCs after treatment

We analyzed total ILCs (CD45⁺Lin⁺CD127⁺CD161⁺) and group 1, 2, and 3 ILC subsets in whole blood (Figure S6). The circulating numbers and percentages of ILC2s (CD45⁺Lin⁺CD127⁺CD161⁺CRTH2⁺) showed no significant difference between asthma patients and healthy controls at baseline. Notably, the frequency of ILC2s significantly in relation to other identifiable ILC populations decreased after 21 days in EA patients (Figure 3A and 3). The frequency of ILC1s and ILC3s NCR⁺ and NCR⁺ also showed no significant difference between asthma patients and healthy controls at baseline (Figure S7 A-C). The frequency of ILC1s was increased (CD45⁺Lin⁺CD127⁺CD161⁺c-kit⁺CRTH2⁺) in NN patients after treatment (Figure S7A). We did not find any correlation between circulating ILC2s and serum cytokine levels (Figure 3C).




FIGURE 1 Type 2 endotype is predominant in EA patients and there is reduction of type 2 endotype after treatment in high altitude. Absolute total number of peripheral blood eosinophils (A), numbers and frequency of activated CRTH2⁺ eosinophils (CD11b⁺CD16⁻Siglec8⁺CCR3⁺CRTH2⁺CD69⁺) (B) and serum IL-5, IL-13 and EDN levels (C) of eosinophilic allergic asthma (EA), $n = 9$, noneosinophilic allergic asthma (NA), $n = 9$, noneosinophilic nonallergic asthma (NN), $n = 8$, and healthy control (HC), $n = 9$ compared between baseline (red dot) and 21 days (blue dot) of the treatment. D, Serum IL-5, IL-13 and EDN levels correlated with absolute eosinophils. E, Heat map Spearman's correlation between serum cytokine levels and eosinophils and activated eosinophils in different asthma phenotypes. * $P < .05$, ** $P < .01$, *** $P < .001$, **** $P < .0001$




FIGURE 2 CRTH2⁺ cells decrease over 21 d in all asthma subgroups after treatment in high altitude. A-C, Numbers and frequency of CRTH2 expression on Th (CD4⁺CD25⁻), Treg (CD4⁺CD25⁺CD127⁻) and Tc (CD8⁺) of eosinophilic allergic asthma (EA), $n = 9$, noneosinophilic allergic asthma (NA), $n = 9$, noneosinophilic nonallergic asthma, $n = 8$, and healthy control (HC), $n = 9$ compared between baseline (red dot) and 21 d (blue dot) of the treatment. D, Heat map Spearman's correlation between serum IL-5 and IL-13 levels and T cell subsets in different asthma phenotypes. * $P < .05$, ** $P < .01$, *** $P < .001$, **** $P < .0001$

3.5 | High altitude decreased response to PGD2 stimulation in CRTH2-expressing ILCs and T cell

To determine the effect of treatment on the functional PGD2 response in ILCs and T cell subsets, we stimulated whole blood with PGD2 and measured the frequency of activated (CD69⁺) cells. In unstimulated whole blood, we could not detect any significant difference on activated cell numbers between baseline and after 21 days of treatment in high altitude in asthma patients (Figure 4A-D). In PGD2-stimulated whole blood, CD69⁺ ILC2s as a proportion of ILC2s were significantly decreased in asthma patients after 21 days in Davos, while there was no change in healthy controls (Figure 4A and Figure S8A). Interestingly, activated CD4⁺CD25⁻CRTH2⁺, CD4⁺CD25⁺CD127⁻CRTH2⁺, and CD8⁺CRTH2⁺ T cells were strikingly reduced after 21 days of treatment in PGD2-stimulated peripheral blood of asthma patients

(Figure 4B-D and Figure S8B-D). We also found the frequency of CD69⁺CD8⁺CRTH2⁺ T cells in asthma patients was higher at baseline in PGD2-stimulated whole blood compared to healthy controls (Figure 4D).

3.6 | Decreased suppressive function in CRTH2 expressing Tregs

We next assessed functional properties of Tregs with and without CRTH2 expression. There was a relatively weak suppressor function of CRTH2 positive Tregs of asthma patients, which was partially reconstituted after 21 days of treatment (Figure 5A). In PGD2-stimulated cultures, the frequency of T effector cell proliferation was also higher when cultured with CRTH2⁺ Tregs compared to CRTH2⁻ Tregs (Figure 5A). Moreover, CRTH2⁺ Tregs






FIGURE 3 Decreased type 2 innate lymphoid cells (ILC2s) in type 2 endotype after treatment in high altitude. A, Representative flow cytometry dot plot of ILCs. Expression of CRTH2 defined type 2 innate lymphoid cells (ILC2s). Data are shown as means. B, Numbers and frequency of ILC2s of eosinophilic allergic asthma (EA), $n = 9$, noneosinophilic allergic asthma (NA), $n = 9$, noneosinophilic nonallergic asthma (NN), $n = 8$, and healthy control (HC), $n = 9$ compared between baseline (red dot) and 21 d (blue dot) of the treatment. C, Heat map Spearman's correlation between serum IL-5 and IL-13 levels and ILC2s in different asthma phenotypes. * $P < .05$, ** $P < .01$




showed less suppressive function in the PGD2-stimulated cultures, whereas PGD2 stimulation showed no effect with CRTH2⁺ Tregs. We also analyzed the supernatants in the cells cultured and found IL-4 levels to be significantly higher in CRTH2⁺ Tregs with PGD2 stimulation (Figure 5B). Thus, we demonstrated that CRTH2⁺ Tregs had defective suppressive function after PGD2 stimulation, which partially recovered after 21 days of treatment.

3.7 | Asthma control, FEV1, and exhaled nitric oxide correlated with immune responses

Overall, altitude treatment significantly improved asthma control, lung function, and significantly decreased lung inflammation in asthma patients (Figure S9A). FeNO levels had a positive correlation with the number of eosinophils, activated eosinophils, and serum IL-5 in asthma patients, and correlated negatively with the number of CRTH2⁺ Tc cells (Figure S9B). Improved lung function correlated with reduced numbers of lymphocytes, CRTH2⁺ Th cells, and eosinophils (Figure S9B).

In the asthma phenotype analysis, patients with EA and NEA showed significantly increased asthma control after treatment (Figure 6A). Improved asthma control that determined by increased ACT score in EA patients showed a strong correlation with decreased number and frequency of CRTH2⁺ Treg cells (Figure 6B). Furthermore, FeNO levels had a negative correlation with the number and frequency of CRTH2⁺ Tc cells (Figure 6C). In NEA patients, improved lung function correlated with decreased lymphocytes and FeNO levels and had a negative correlation with the number of CRTH2⁺ Tc cells (Figure 6C). In NN patients, ACT scores had a positive correlation with the number and frequency of CRTH2⁺ Th cells. Also, FEV1 levels correlated with FeNO levels, serum EDN levels, and lymphocytes (Figure 6C). Furthermore, FeNO levels showed a negative correlation with lymphocytes in NN patients (Figure 6C). The network analyses of immune markers in the different phenotype of asthma showed differences in correlation between eosinophils, T cell subsets, ILC2s, and clinical responses (Figure S9C). A strong correlation network was observed in eosinophilic and allergic asthma, whereas there was a weak

FIGURE 4 Reduced sensitization of CRTH2⁺ cells after treatment in high altitude A-D, Frequency of activated (CD69⁺) CRTH2⁺ ILCs, CRTH2⁺CD4⁺CD25⁺, CRTH2⁺CD4⁺CD25⁺CD127⁺ and CRTH2⁺CD8⁺ T cells compared between before and after 1 h PGD2 stimulation of 8 asthma patients (2 EA, 4 NA and 2 NN) and 4 healthy controls. **P* < .05, ***P* < .01



correlation in noneosinophilic nonallergic asthma. Heat map correlation and correlation graphs between asthma phenotypes are shown in Figure S10A. The duration of asthma in noneosinophilic patients had negative correlation with the frequency of CRTH2⁺Th and CRTH2⁺Treg cells (Figure S10B).

4 | DISCUSSION


Asthma treatment in high altitude has been shown to improve asthma control, quality of life, pulmonary function, decrease lung inflammation (decreased exhaled nitric oxide), and reduce oral corticosteroids use in asthma patients.^{28,31} High-altitude climates have low concentrations of house dust mite (HDM) due to increased altitude and decreased humidity.³² In addition, exposure to fungal spores, molds, and pollen are shorter in duration and lower in concentration at high altitude,³³ resulting in reduced bronchial hyperresponsiveness, total blood eosinophils, eosinophilic cationic protein, and HDM-IgE level.³⁴ This study enrolled the patients during the period of early winter to end summer, therefore controlling for the avoidance of the relevant allergen (grass and tree pollen) during the season. High altitude may have a direct physiological

benefit because of the lower oxygen concentration and viscosity of the air that promoted the full expansion of the lungs and decreased lung resistance.³⁵ Moreover, moving away from psychological stress is an add-on which may also affect neuroimmune mediators with reduced airway inflammation and triggers of asthma exacerbation.^{36,37} Other factors related to the exposome (eg, pollution, traffic, and healthier diet while in hospital, etc) might account for the changes observed.

This study brings together several novel approaches to detail the functional immune response during 21 days of treatment in high altitude, while showing that asthma treatment in high altitude simultaneously improved asthma control, FEV1 and FeNO, while modifying the immunological characteristics of effector cells known to contribute to eosinophilic and allergic inflammation. This study had certain limitations, such as another group of asthma patients for comparison in a similar clinical setting at low altitude. In addition, sampling of bronchial samples was lacking, such as induced sputum and bronchoalveolar lavage.

In eosinophilic and allergic asthma, type 2 immune response is a significant driver of asthma pathology.^{38,39} CRTH2 is the hallmark of both Th2 and ILC2 and regarded as a potent inducer of type 2 cytokine secretion. We show that serum IL-5, IL-13, and

FIGURE 6 A, Asthma control test (ACT) score, force expiratory volume in 1 s (FEV1) and exhaled nitric oxide (FeNO) in patients with eosinophilic allergic asthma (EA), *n* = 9, noneosinophilic allergic asthma (NA), *n* = 9 and noneosinophilic nonallergic asthma (NN), *n* = 8 compared baseline (red dot) and 21 d (blue dot) of the treatment. B, Correlation between ACT score and CRTH2⁺ Tregs in EA patients. C, Heat map Spearman's correlation between clinical responses and immunological responses in different asthma phenotypes. **P* < .05, ***P* < .01



2 immune response, mostly evident in allergic, eosinophilic asthma patients. Furthermore, desensitization of the CRTH2 system was shown in all asthma phenotypes, indicating a potential implication of the CRTH2 pathway not only in eosinophilic asthma patients.

ACKNOWLEDGMENT

This study was supported by Christine Kühne-Center for Allergy Research and Education (CK-CARE) and Idorsia Pharmaceuticals. We acknowledge Britta Stolpe from Hochgebirgsklinik Davos for taking care of the participants and Geoffroy Bourquin from the Idorsia Research Biobank for sample and data management. The authors thank Rene Roscher (Idorsia Pharmaceuticals Ltd.) and Katharina Wartha (Idorsia Pharmaceuticals Ltd.) for the support provided on study design and setup.

CONFLICTS OF INTEREST

Andrew L. Croxford, Herve Farine, Peter MA Groenen, Martine Clozel and Daniel S. Strasser are Idorsia employees and have received shares and options.

AUTHOR CONTRIBUTIONS

GC, HWD, EDR, and CA planned the study. TB, NL, and PS carried out the experiment. TB, ALC, HF, DSS, MA, and CA conceived and planned the experiments. TB wrote the manuscript with support from DSS, MS, and CA. GC, HWD, JS, EDR, PK recruited the participants. AD, BR, and DM prepared the samples. GT was analysis of statistics. PMAG, EDR, MC, and CA supervised the study.

ORCID

Tadech Boonpiyathad  <https://orcid.org/0000-0001-8690-7647>

Ge Tan  <https://orcid.org/0000-0003-0026-8739>

Mübecce Akdis  <https://orcid.org/0000-0002-9228-4594>

REFERENCES

- Agache I, Akdis C,utel M, Virchow JC. Untangling asthma phenotypes and endotypes. *Allergy*. 2012;67(7):835-846.
- Del Giacco SR, Bakirtas A, Bel E, et al. Allergy in severe asthma. *Allergy*. 2017;72(2):207-220.
- Agache I, Akdis CA. Endotypes of allergic diseases and asthma: an important step in building blocks for the future of precision medicine. *Allergol Int*. 2016;65(3):243-252.
- Tan H-T, Hagner S, Rucht F, et al. Tight junction, mucin, and inflammasome-related molecules are differentially expressed in eosinophilic, mixed, and neutrophilic experimental asthma in mice. *Allergy*. 2019;74(2):294-307.
- Genuneit J, Seibold AM, Apfelbacher CJ, et al. Overview of systematic reviews in allergy epidemiology. *Allergy*. 2017;72(6):849-856.
- Odling M, Andersson N, Ekstrom S, Melen E, Bergstrom A, Kull I. Characterization of asthma in the adolescent population. *Allergy*. 2018;73(8):1744-1746.
- Su M-W, Lin W-C, Tsai C-H, et al. Childhood asthma clusters reveal neutrophil-predominant phenotype with distinct gene expression. *Allergy*. 2018;73(10):2024-2032.
- Dunn RM, Busse PJ, Wechsler ME. Asthma in the elderly and late-onset adult asthma. *Allergy*. 2018;73(2):284-294.
- Worth L, Michel S, Gaertner VD, Kabesch M, Schieck M. Asthma- and IgE-associated polymorphisms affect expression of TH 17 genes. *Allergy*. 2018;73(6):1342-1347.
- Terl M, Sedláč V, Cap P, et al. Asthma management: a new phenotype-based approach using presence of eosinophilia and allergy. *Allergy*. 2017;72(9):1279-1287.
- Rodrigo-Muñoz JM, Cañas JA, Sastre B, et al. Asthma diagnosis using integrated analysis of eosinophil microRNAs. *Allergy*. 2019;74(3):507-517.
- Johansson MW. Activation states of blood eosinophils in asthma. *Clin Exp Allergy*. 2014;44(4):482-498.
- Jandl K, Heinemann A. The therapeutic potential of CRTH2/DP2 beyond allergy and asthma. *Prostaglandins Other Lipid Mediat*. 2017;133:42-48.
- Lingblom C, Käppi T, Bergquist H, et al. Differences in eosinophil molecular profiles between children and adults with eosinophilic esophagitis. *Allergy*. 2017;72(9):1406-1414.
- Sokolowska M, Chen L-Y, Liu Y, et al. Dysregulation of lipidomic profile and antiviral immunity in response to hyaluronan in patients with severe asthma. *J Allergy Clin Immunol*. 2017;139(4):1379-1383.
- Crea AE, Nakhosteen JA, Lee TH. Mediator concentrations in bronchoalveolar lavage fluid of patients with mild asymptomatic bronchial asthma. *Eur Respir J*. 1992;5(2):190-195.
- Bochenek G, Nizankowska E, Gielicz A, Swierczynska M, Szczeklik A. Plasma 9alpha, 11beta-PGF2, a PGD2 metabolite, as a sensitive marker of mast cell activation by allergen in bronchial asthma. *Thorax*. 2004;59(6):459-464.
- Murata T, Lin MI, Aritake K, et al. Role of prostaglandin D2 receptor DP as a suppressor of tumor hyperpermeability and angiogenesis in vivo. *Proc Natl Acad Sci U S A*. 2008;105(50):20009-20014.
- Xue L, Gyles SL, Wetley FR, et al. Prostaglandin D2 causes preferential induction of proinflammatory Th2 cytokine production through an action on chemoattractant receptor-like molecule expressed on Th2 cells. *J Immunol*. 2005;175(10):6531-6536.
- Palikhe NS, Laratta C, Nahirney D, et al. Elevated levels of circulating CD4(+) CRTh2(+) T cells characterize severe asthma. *Clin Exp Allergy*. 2016;46(6):825-836.
- Doherty TA, Broide DH. Group 2 innate lymphoid cells: new players in human allergic diseases. *J Invest Allergol Clin Immunol*. 2015;25(1):1-11.
- Aron JL, Akbari O. Regulatory T cells and type 2 innate lymphoid cell-dependent asthma. *Allergy*. 2017;72(8):1148-1155.
- Chen R, Smith SG, Salter B, et al. Allergen-induced Increases in sputum levels of group 2 innate lymphoid cells in subjects with asthma. *Am J Respir Crit Care Med*. 2017;196(6):700-712.
- Barnig C, Cernadas M, Dutile S, et al. Lipoxin A4 regulates natural killer cell and type 2 innate lymphoid cell activation in asthma. *Sci Transl Med*. 2013;5(174):174ra26.
- Yu QN, Guo YB, Li X, et al. ILC2 frequency and activity are inhibited by glucocorticoid treatment via STAT pathway in patients with asthma. *Allergy*. 2018;73(9):1860-1870.
- Sugita K, Steer CA, Martinez-Gonzalez I, et al. Type 2 innate lymphoid cells disrupt bronchial epithelial barrier integrity by targeting tight junctions through IL-13 in asthmatic patients. *J Allergy Clin Immunol*. 2018;141(1):300-310.e11.
- Wawrzyniak P, Wawrzyniak M, Wanke K, et al. Regulation of bronchial epithelial barrier integrity by type 2 cytokines and histone deacetylases in asthmatic patients. *J Allergy Clin Immunol*. 2017;139(1):93-103.

28. Karagiannidis C, Hense G, Rueckert B, et al. High-altitude climate therapy reduces local airway inflammation and modulates lymphocyte activation. *Scand J Immunol*. 2006;63(4):304-310.
29. Heeringa JJ, Fieten KB, Bruins FM, et al. Treatment for moderate to severe atopic dermatitis in alpine and moderate maritime climates differentially affects helper T cells and memory B cells in children. *Clin Exp Allergy*. 2018;48(6):679-690.
30. Schatz M, Sorkness CA, Li JT, et al. Asthma Control Test: reliability, validity, and responsiveness in patients not previously followed by asthma specialists. *J Allergy Clin Immunol*. 2006;117(3):549-556.
31. van de Griendt EJ, Verkleij M, Douwes JM, van Aalderen WM, Geenen R. Problematic severe asthma in children treated at high altitude: tapering the dose while improving control. *J Asthma*. 2014;51(3):315-319.
32. Charpin D. High altitude and asthma: beyond house dust mites. *Eur Respir J*. 2012;40(6):1320-1321.
33. Rijssenbeek-Nouwens LH, Bel EH. High-altitude treatment: a therapeutic option for patients with severe, refractory asthma? *Clin Exp Allergy*. 2011;41(6):775-782.
34. Grootendorst DC, Dahlen S-E, Van Den Bos JW, et al. Benefits of high altitude allergen avoidance in atopic adolescents with moderate to severe asthma, over and above treatment with high dose inhaled steroids. *Clin Exp Allergy*. 2001;31(3):400-408.
35. Skloot G, Permutt S, Toghias A. Airway hyperresponsiveness in asthma: a problem of limited smooth muscle relaxation with inspiration. *J Clin Invest*. 1995;96(5):2393-2403.
36. Sandberg S, Paton JY, Ahola S, et al. The role of acute and chronic stress in asthma attacks in children. *Lancet*. 2000;356(9234):982-987.
37. Chen E, Miller GE. Stress and inflammation in exacerbations of asthma. *Brain Behav Immun*. 2007;21(8):993-999.
38. Blom LH, Martel BC, Larsen LF, et al. The immunoglobulin superfamily member CD200R identifies cells involved in type 2 immune responses. *Allergy*. 2017;72(7):1081-1090.
39. James A, Janson C, Malinovschi A, et al. Serum periostin relates to type-2 inflammation and lung function in asthma: Data from the large population-based cohort Swedish GA(2)LEN. *Allergy*. 2017;72(11):1753-1760.
40. Agache I, Strasser DS, Klenk A, et al. Serum IL-5 and IL-13 consistently serve as the best predictors for the blood eosinophilia phenotype in adult asthmatics. *Allergy*. 2016;71(8):1192-1202.
41. Simon HU, Grotzer M, Nikolaizik WH, Blaser K, Schoni MH. High altitude climate therapy reduces peripheral blood T lymphocyte activation, eosinophilia, and bronchial obstruction in children with house-dust mite allergic asthma. *Pediatr Pulmonol*. 1994;17(5):304-311.
42. Pin I, Freitag AP, O'Byrne PM, et al. Changes in the cellular profile of induced sputum after allergen-induced asthmatic responses. *Am Rev Respir Dis*. 1992;145(6):1265-1269.
43. Hartnell A, Robinson DS, Kay AB, Wardlaw AJ. CD69 is expressed by human eosinophils activated in vivo in asthma and in vitro by cytokines. *Immunology*. 1993;80(2):281-286.
44. Pignatti P, Perfetti L, Galdi E, et al. Increased CD69 expression on peripheral blood eosinophils after specific inhalation challenge. *Allergy*. 2002;57(5):411-416.
45. Peters SP. Asthma phenotypes: nonallergic (intrinsic) asthma. *J Allergy Clin Immunol Pract*. 2014;2(6):650-652.
46. Zhao J, Lloyd CM, Noble A. Th17 responses in chronic allergic airway inflammation abrogate regulatory T-cell-mediated tolerance and contribute to airway remodeling. *Mucosal Immunol*. 2013;6(2):335-346.
47. Stinson SE, Amrani Y, Brightling CE. D prostanoid receptor 2 (chemoattractant receptor-homologous molecule expressed on TH2 cells) protein expression in asthmatic patients and its effects on bronchial epithelial cells. *J Allergy Clin Immunol*. 2015;135(2):395-406.
48. Fajt ML, Gelhaus SL, Freeman B, et al. Prostaglandin D(2) pathway upregulation: relation to asthma severity, control, and TH2 inflammation. *J Allergy Clin Immunol*. 2013;131(6):1504-1512.
49. Robinson DS, Hamid Q, Ying S, et al. Predominant TH2-like bronchoalveolar T-lymphocyte population in atopic asthma. *N Engl J Med*. 1992;326(5):298-304.
50. Cosmi L, Annunziato F, Iwasaki M, et al. CCR2 is the most reliable marker for the detection of circulating human type 2 Th and type 2 T cytotoxic cells in health and disease. *Eur J Immunol*. 2000;30(10):2972-2979.
51. Xue L, Fergusson J, Salimi M, et al. Prostaglandin D2 and leukotriene E4 synergize to stimulate diverse TH2 functions and TH2 cell/neutrophil crosstalk. *J Allergy Clin Immunol*. 2015;135(5):1358-1366.e1-11.
52. Roediger B, Kyle R, Yip KH, et al. Cutaneous immunosurveillance and regulation of inflammation by group 2 innate lymphoid cells. *Nat Immunol*. 2013;14(6):564-573.
53. Mitthamsiri W, Pradubongsap P, Sangasapaviliya A, Boonpiyathad T. Decreased CCR2 expression and response to allergen re-stimulation on innate lymphoid cells in patients with allergen-specific immunotherapy. *Allergy Asthma Immunol Res*. 2018;10(6):662-674.
54. Hilvering B, Hinks T, Stöger L, et al. Synergistic activation of pro-inflammatory type-2 CD8(+) T lymphocytes by lipid mediators in severe eosinophilic asthma. *Mucosal Immunol*. 2018;11(5):1408-1419.
55. Gonem S, Berair R, Singapuri A, et al. Fevipiprant, a prostaglandin D2 receptor 2 antagonist, in patients with persistent eosinophilic asthma: a single-centre, randomised, double-blind, parallel-group, placebo-controlled trial. *Lancet Respir Med*. 2016;4(9):699-707.
56. Bateman ED, Guerrerros AG, Brockhaus F, et al. Fevipiprant, an oral prostaglandin DP2 receptor (CRTh2) antagonist, in allergic asthma uncontrolled on low-dose inhaled corticosteroids. *Eur Respir J*. 2017;50(2):1700670.
57. Pettipher R, Hunter MG, Perkins CM, et al. Heightened response of eosinophilic asthmatic patients to the CCR2 antagonist OC000459. *Allergy*. 2014;69(9):1223-1232.
58. Hall IP, Fowler AV, Gupta A, et al. Efficacy of BI 671800, an oral CCR2 antagonist, in poorly controlled asthma as sole controller and in the presence of inhaled corticosteroid treatment. *Pulm Pharmacol Ther*. 2015;32:37-44.

SUPPORTING INFORMATION

Additional supporting information may be found online in the Supporting Information section at the end of the article.

How to cite this article: Boonpiyathad T, Capova G, Duchna H-W, et al. Impact of high-altitude therapy on type-2 immune responses in asthma patients. *Allergy*. 2020;75:84-94. <https://doi.org/10.1111/all.13967>